Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

LMTX

- PMLiVE

New Swedish study finds HSCT can slow progression of multiple sclerosis

More than 70% of participants in the study had no new progression after five years of treatment

- PMLiVE

NIHR partners with Motor Neurone Disease Association for MND research

The partnership will speed up the discovery of treatments and insights for MND

- PMLiVE

AbbVie announces acquisition of Mitokinin in deal worth over $650m

The agreement gives AbbVie access to a potential treatment for Parkinson’s disease

- PMLiVE

Eli Lilly to acquire cancer specialist Point Biopharma in deal worth $1.4bn

The transaction would give Lilly access to experimental radioligand therapies

- PMLiVE

Alzheimer’s Research UK awards Cardiff University researchers £387,000

The researchers will investigate how genes accelerate the development of Alzheimer’s disease

- PMLiVE

Alzheimer’s Research UK launches ‘Change The Ending’ campaign

A survey revealed that 22% of 2,162 people were unaware of the impact dementia has on people’s everyday lives

- PMLiVE

Eli Lilly files US lawsuits over ‘unlawful’ sales of Mounjaro counterfeits

Lilly is the only FDA-approved company to legally sell products containing tirzepatide

- PMLiVE

Researchers discover how neurons die in Alzheimer’s disease

The findings open up potential avenues to develop new treatments for the condition

- PMLiVE

AbbVie shares positive results from head-to-head study of Skyrizi in Crohn’s disease

The late-stage study has been evaluating the drug against Johnson & Johnson’s Stelara

- PMLiVE

AstraZeneca’s rare disease unit partners with Verge Genomics in deal worth over $840m

Both will identify drug targets for neurodegenerative and neuromuscular diseases

- PMLiVE

Eli Lilly’s Mounjaro receives NICE recommendation to treat type 2 diabetes

Around 180,000 patients with type 2 diabetes could benefit from the new treatment option

- PMLiVE

Boehringer and Lilly’s Jardiance granted MHRA approval to treat chronic kidney disease

Approximately 7.2 million people in the UK are affected by the long-term kidney condition

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links